Drugs / Messenchymal stem cell secretome
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05925647 | Aug 2022 → Feb 2023 | rheumatoid arthritis | Universitas Sebelas Maret | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Messenchymal stem cell secretome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05925647 ↗ |
| Known as | Mesenchymal stem cell secretome | “Mesenchymal stem cell secretome obtained from Kalbe Pharma Company” NCT05925647 ↗ |